Eligibility to buy research-use-only material rests on two things: that the buyer is an organisation doing laboratory research, and that the material is going into that research rather than to a person. Neither is established by holding a particular licence, which is the most common misunderstanding in this area.
Research use only explained covers what the designation itself means. This guide covers the buyer side of it.
What the designation is actually about
Research use only is a statement of intended use. Regulators read intended use from everything a seller says and does, not only from a label, and the same logic runs toward the buyer: an organisation that buys as a research entity and uses the material that way is doing what the designation describes.
That is why a supplier asks what kind of organisation you are rather than only asking for a number.
Who typically qualifies
- Research institutions, universities and their affiliated laboratories.
- Commercial laboratories conducting analytical or in-vitro work.
- Companies carrying out formulation, method development or reference-standard work.
- Clinical or veterinary practices operating a defined research programme, where the material stays inside that programme.
What does not establish eligibility
| Often assumed to qualify you | Why it does not | What actually matters |
|---|---|---|
| A professional licence | A licence authorises practice, not purchase of research chemicals | Whether the organisation runs research |
| A business tax ID | It establishes an entity exists, nothing more | The nature of the entity's work |
| Signing a disclaimer | An acknowledgement is not a qualification | Actual intended use |
| Buying through a company | The entity can be anything | What the entity does with the material |
| A resale certificate | It is a tax instrument | Unrelated to eligibility |
Each left-hand item is commonly offered as proof of eligibility and establishes something else.
What a supplier is checking at account opening
Three things, and the account application is built around them: that the entity is real and reachable, that its stated category is consistent with research use, and that it has acknowledged the restriction in terms specific enough to mean something.
A supplier who checks none of this is not being accommodating. They are carrying a risk that eventually attaches to their buyers too, because an enforcement action against a seller reaches the records of who they sold to.
Where the line sits inside a practice
A practice that also runs a research programme is in a position that depends entirely on separation. Material bought as research material belongs to the research programme: stored separately, recorded separately, and not drawn on for anything outside it. Where that separation is not documented, it is not visible to anyone looking later.
Chain of custody inside a practice covers how that separation is actually maintained, and records to keep covers what shows it happened.
What the supplier is exposed to, and why it reaches you
Enforcement in this area has consistently turned on intended use read from everything a seller says and does, rather than on a label alone. A supplier whose marketing describes effects in people has created evidence about intended use regardless of what the vial says.
That matters to a buyer for a practical reason: an action against a seller reaches their records, and their records include who they sold to. Buying from a supplier whose public material reads as consumer marketing attaches you to that position whether or not your own use is impeccable.
Signals that a supplier is treating the designation seriously
- An eligibility question at account opening that asks what the organisation does, not merely a checkbox.
- Site copy that describes molecules, methods and documentation rather than outcomes in people.
- No reference to quantities per person, schedules or anything resembling administration guidance.
- Restriction language on the product record itself, under its own heading, rather than only in a footer.
What this guide is not
It is not legal advice, and the position varies by jurisdiction and by the nature of the organisation. Where a programme is being set up, the question is worth putting to counsel once, properly, rather than inferred from supplier policies. What a supplier's policy tells you is what that supplier requires, not what the law requires of you.
This sits inside the wider picture of what gets tested and why, which why peptide testing matters sets out across the whole analytical panel.